Pharmaceutical News

RSS

American Crystallographic Association analysis may help researchers design vaccine against HIV/AIDS

Designing an effective HIV/AIDS vaccine is something of a paradox: a good vaccine would be safe and look enough like HIV to kick-start the immune system into neutralizing the virus - but the problem is that this is exactly what the human immune system has trouble doing even when it's exposed to the real thing.

19 Jul 2013

Oxytocin may not improve symptoms of children with autism, study finds

The so-called trust hormone, oxytocin, may not improve the symptoms of children with autism, a large study led by researchers at the University of New South Wales has found.

19 Jul 2013

New data identifies specific cellular pathways by which RNS60 impacts Alzheimer's Disease

On Wednesday Revalesio Corporation presented new data at the Alzheimer's Association International Conference that identifies the specific cellular pathways by which Revalesio's lead investigational product, RNS60, impacts Alzheimer's Disease. This research, conducted in partnership with Rush University Medical Center, investigates a new category of therapeutics using Revalesio's novel nanotechnology platform.

19 Jul 2013

Metabolomics tools predict who can benefit from treatment with certain antidepressants

Duke Medicine researchers have identified biochemical changes in people taking antidepressants - but only in those whose depression improves. These changes occur in a neurotransmitter pathway that is connected to the pineal gland, the part of the endocrine system that controls the sleep cycle, suggesting an added link between sleep, depression and treatment outcomes.

19 Jul 2013

Nanotechnology drug kills brain-tumor cells and retards growth of tumor blood vessels

An experimental drug in early development for aggressive brain tumors can cross the blood-brain tumor barrier and kill tumor cells and block the growth of tumor blood vessels, according to a study led by researchers at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James).

19 Jul 2013

Idera Pharmaceuticals receives patent related to IMO-8400

Idera Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office has issued to Idera patent number 8,486,908, providing both composition of matter and method of use protection for IMO-8400.

19 Jul 2013

FDA grants orphan drug designation to ARMAGEN's AGT-182 for treatment of Hunter syndrome

ARMAGEN announced today that the U.S. Food and Drug Administration has granted orphan drug designation to its lead product AGT-182 for the treatment of mucopolysaccharidosis type II (also known as Hunter syndrome or MPS II).

19 Jul 2013

Par Pharmaceutical receives final ANDA approval for generic version of Trilipix

Par Pharmaceutical Companies, Inc. today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for fenofibric acid EQ 45 mg and EQ 135 mg delayed-release capsules.

19 Jul 2013

Bausch + Lomb obtains option to license MIM-D3 for treatment of dry eye syndrome

Bausch + Lomb, the global eye health company, and Mimetogen Pharmaceuticals Inc. today announced that Bausch + Lomb has acquired an option to license an investigational compound currently in Phase 2 development for the treatment of dry eye syndrome, a condition that affects millions of people worldwide.

19 Jul 2013

Boys more likely to receive HPV4 vaccine if their mothers receive flu shots, study finds

Boys are more likely to receive the quadrivalent human papillomavirus vaccine if their mothers receive flu shots or Pap screenings, according to a Kaiser Permanente study published in the American Journal of Public Health.

19 Jul 2013

Ensemble Therapeutics announces initiation of drug discovery collaboration with Alexion subsidiary

Ensemble Therapeutics, a biotechnology company developing Ensemblins, a novel class of small molecule therapeutics with the potential to modulate targets typically addressed by biologics, today announced the initiation of a drug discovery collaboration with a subsidiary of Alexion Pharmaceuticals, Inc., the global biopharmaceutical company focused on developing and commercializing life-transforming therapies for patients with life-threatening, ultra-rare disorders.

18 Jul 2013

Study brings new hope for patients with metastatic prostate cancer

A study of a new radiotherapeutic drug published this week in the New England Journal of Medicine brings fresh hope for a particular group of cancer patients that otherwise suffer and ultimately die from the disease -- those with prostate cancer that has spread to their bones and has failed to be controlled by hormone deprivation drugs.

18 Jul 2013

Quest Diagnostics completes sale of ibrutinib commercialization rights to Royalty Pharma

Quest Diagnostics Incorporated, the world's leading provider of diagnostic information services, announced today that it has completed the sale of its rights to royalties from commercialization of the drug candidate ibrutinib to Royalty Pharma, the industry leader in acquiring royalty interests in marketed and late stage biopharmaceutical products, for $485 million in cash.

From Quest Diagnostics 18 Jul 2013

Transition Therapeutics' ELND005 receives Fast Track Designation from FDA

Transition Therapeutics Inc. announced that the US Food and Drug Administration has granted Fast Track Designation to the development program for ELND005 which was submitted for the treatment of Neuropsychiatric Symptoms in Alzheimer's disease.

18 Jul 2013

TSRI scientists study 3-D structure of glucagon receptor for treatment of diabetes

The study is reported on July 17, 2013, in an advance online edition of the journal Nature, alongside a British laboratory's structural study of another member of the same class of receptors-known as "class B" G protein-coupled receptors (GPCRs).

18 Jul 2013

Children exposed to AEDs in womb at risk of early development issues: Study

Children whose mothers took antiepileptic drugs while pregnant are at increased risk of early development issues, according to a new study published in Epilepsia, a journal published by Wiley on behalf of the International League Against Epilepsy.

18 Jul 2013

AbGenomics raises $9.6M for advancing therapeutic antibodies for autoimmune diseases, cancers

AbGenomics International announced today that it has raised $9.6 million in current financing round.

18 Jul 2013

Single dose of methylphenidate can reduce risk of falls among elderly adults

Ben-Gurion University of the Negev researchers have discovered that a single dose of methylphenidate, used to treat Attention Deficit Hyperactivity Disorder and narcolepsy, helps to improve balance control during walking, hence reducing the risk of falls among elderly adults.

18 Jul 2013

Adynxx receives FDA Fast Track designation for AYX1 Injection to treat chronic pain

Adynxx, a clinical-stage pharmaceutical company developing a first-in-class platform of therapeutics to address pain at its molecular roots, announced today that the U.S. Food and Drug Administration has granted Fast Track designation to AYX1 Injection for the prevention of chronic pain.

17 Jul 2013

Sequella licenses Pfizer's exclusive worldwide rights to develop, commercialize sutezolid

Sequella, a clinical-stage pharmaceutical company commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it has licensed Pfizer Inc's exclusive worldwide rights to develop and commercialize sutezolid, a Phase 2 oxazolidinone antibiotic currently in development for the treatment of tuberculosis.

17 Jul 2013

Pharmaceutical News

American Crystallographic Association analysis may help researchers design vaccine against HIV/AIDS

Oxytocin may not improve symptoms of children with autism, study finds

New data identifies specific cellular pathways by which RNS60 impacts Alzheimer's Disease

Metabolomics tools predict who can benefit from treatment with certain antidepressants

Nanotechnology drug kills brain-tumor cells and retards growth of tumor blood vessels

Idera Pharmaceuticals receives patent related to IMO-8400

FDA grants orphan drug designation to ARMAGEN's AGT-182 for treatment of Hunter syndrome

Par Pharmaceutical receives final ANDA approval for generic version of Trilipix

Bausch + Lomb obtains option to license MIM-D3 for treatment of dry eye syndrome

Boys more likely to receive HPV4 vaccine if their mothers receive flu shots, study finds

Ensemble Therapeutics announces initiation of drug discovery collaboration with Alexion subsidiary

Study brings new hope for patients with metastatic prostate cancer

Quest Diagnostics completes sale of ibrutinib commercialization rights to Royalty Pharma

Transition Therapeutics' ELND005 receives Fast Track Designation from FDA

TSRI scientists study 3-D structure of glucagon receptor for treatment of diabetes

Children exposed to AEDs in womb at risk of early development issues: Study

AbGenomics raises $9.6M for advancing therapeutic antibodies for autoimmune diseases, cancers

Single dose of methylphenidate can reduce risk of falls among elderly adults

Adynxx receives FDA Fast Track designation for AYX1 Injection to treat chronic pain

Sequella licenses Pfizer's exclusive worldwide rights to develop, commercialize sutezolid

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News